🌍·1d agoResearch
Cost-effectiveness and value implications of veligrotug versus teprotumumab for moderate-to-severe thyroid eye disease in the United States.
Publisher
E
Europe PMC
EU
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Europe PMC
- Region
- EU
- Scope
- Research
- Published
- September 21, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on europepmc.org
Leave the platform to read the original full article on the publisher site.
Source: Europe PMC
Scope: Research
Related coverage
More related coverage
Crossref/17h ago
Summary for Patients: Tobacco Use Treatment: Synopsis of the 2026 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
Crossref/17h ago
Hybrid endoscopic submucosal dissection enhances efficiency with comparable curative outcomes: a Bayesian meta-analysis, systematic review, and Monte Carlo simulation of randomized controlled trials
Crossref/17h ago
Advances, Risks, And Implementation Challenges of Artificial Intelligence as A Force Multiplier for Clinical Decision Making and Health System Efficiency
Crossref/17h ago